MDXG MiMedx Group Inc.

MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall

MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall

Company to Sponsor Lunch Symposium and Hands-On Skills Lab

Featuring Seven Accepted Posters, Further Expanding Its Best-In-Class Portfolio of Clinical and Scientific Research  

MARIETTA, Ga., Oct. 01, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place October 2-5 in Las Vegas, NV. SAWC Fall is the largest gathering of advanced wound care industry and healthcare professionals and serves as an educational forum to connect with this global community.

“Our research and clinical teams have continued to extend our leadership in expanding the understanding of placental tissue’s unique characteristics and potential clinical benefits,” said Dr. John R. Harper, Ph.D., MIMEDX Chief Scientific Officer. “At SAWC this year, we are proud to once again highlight new research on our product portfolio in two areas that are key to the wound healing cascade, namely inflammation and epithelialization. We continue striving to lead the field in scientific publications and Level I clinical data. In addition, we are excited to connect with attendees with valuable sessions, including a hands-on skills lab that will provide a deep dive into innovative treatment techniques.”   

In addition to the events highlighted below, MIMEDX sales representatives and medical science liaisons will be onsite during exhibit hall hours at booth 511 to discuss the latest product news and clinical information.

Sponsored Lunch Symposium

Wound Care Evolution: Patients Change, Practices Change, Payors Change: Providers Adapt

Date/Time: Thursday, October 3 / 11:40 a.m. – 1:10 p.m. PDT

Faculty: Ehab Sorial, MD, FACS; Naz Wahab, MD, FAAFP, FAPWCA; Dorothy Kurtz Phelan, DPM, D.BFAS, FACFAS; Allyn Forsyth, PhD

Description: This symposium will cover the rapidly changing landscape of wound care, particularly around the use and reimbursement of skin substitutes. As patient populations shift and treatment methodologies evolve, healthcare professionals must stay ahead of the curve to provide optimal care.

Hands-On Skills Lab (CME-Eligible)

Overcoming Challenges in Assessing and Managing Lower Extremity Wounds: Hands-On Workshop

Date/Time: Thursday, October 3 / 1:20 p.m. – 4:40 p.m. PDT

Moderator: Pamela Scarborough, PT, DPT, CWS, FAAWC

MIMEDX Presenter: Randall Spencer

Description: This hands-on workshop will explore innovative treatment techniques for the most common lower extremity wounds. Attendees will engage in experiential learning through product demonstrations of debridement technologies, compression therapy, negative pressure wound therapy, skin substitutes, and more.

Accepted Poster Presentations

The Company is pleased to announce that seven clinical and scientific posters have been accepted and will be on display in the poster hall. 

Clinical Research

  • Chronic Pressure Injuries: More than Taking the Pressure off with Lyophilized Human Amnion/Chorion Membrane
  • Dehydrated Human Amnion Chorion Membrane for Reconstruction of Cutaneous Defects Following Mohs Surgery: A Propensity Score-Matched Comparative Cost-Effectiveness Analysis
  • Survey of Patients with Hard-to-Heal Wounds
  • The Impacts of Medicaid Status on Venous Leg Ulcer Outcomes
  • Pyoderma Gangrenosum: A Light at the End of the Tunnel for an Orphan Disease: Dehydrated Human Amnion/Chorion Membrane

Scientific Research

  • Lyophilized Human Amnionic Membrane Modulates the Macrophage Response During Wound Healing
  • Tri-Layer Amniotic Membrane Allografts Promotes Re-Epithelialization In Vitro via cJUN Mediated Mechanism

About MIMEDX

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit .

Contact:

Matt Notarianni

Investor Relations

470-304-7291



EN
01/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MiMedx Group Inc.

 PRESS RELEASE

MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating an...

MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter Adjusted EBITDA1 was $29 Million, or 25% of Net Sales Company Estimates 2026 Net Sales in a Range of $340-360 Million Announces $100 Million Share Repurchase Program Authorization Management to Host Conference Call Today, February 25, 2026, at 4:30 PM ET MARIETTA, Ga., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Mi...

 PRESS RELEASE

MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financi...

MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25 MARIETTA, Ga., Feb. 17, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, February 25, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be access...

 PRESS RELEASE

MIMEDX Enters into Exclusive Distribution Agreement with Summit Produc...

MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products Agreement expands offering to include additional sheet, particulate and flowable products MARIETTA, Ga., Feb. 04, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Summit Products Group (“Summit”) to distribute three innovative, 510(k) cleared products that complement the Company’s leading Surgical & Wound product portfolio: Hydrelix, NovaForm®, and G4Derm® Plu...

 PRESS RELEASE

MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®

MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX® Industry’s Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publications MARIETTA, Ga., Feb. 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the 15th anniversary of EPIFIX and AMNIOFIX, the Company’s placental allografts used in wound care and surgical recovery settings. “We are thrilled to mark the 15th anniversary of our flagship Wound and Surgical products, EPIFIX and AMNIOFIX, which have been instrumental to our pioneering innovatio...

 PRESS RELEASE

MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®...

MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel Company Continues to Broaden Leading Wound Product Offering MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit®-Wound Gel in the United States. RegenKit®-Wound Gel is an autologous platelet-rich plasma (PRP) and autologous thrombin serum (ATS) wound gel that removes iron-laden red blood cells, while concentrating essential growth factors,...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch